AbbVie - Company Information
AbbVie, Inc. is a research-driven biopharmaceutical company that develops and markets advanced therapies for a wide range of medical conditions, inclu...Read more
Headquarters
Contact
Linkedin
Company Size10,000+
Stock SymbolABBV
Websiteabbvie.com
TypePublic
AbbVie Technology Stack
Find prospects by the technologies they use. Use this section to learn more about key technologies and tools, tracked by 6sense, used by AbbVie
AbbVie Employee Profiles
Are you looking for the decision-makers at AbbVie? Get their email address, phone numbers, and other details from Linkedin or any website. Install and uncover AbbVie’s employee details in less than 30 secs.
Sign-up for 6sense Revenue AI™ for Sales
To find emails, direct dials, and more for prospects across the web.
Sign Up TodayDownload the 6sense Chrome Extension to get verified contact data of AbbVie employees
Install Now
AbbVie News & Press Releases
Sales prospecting needs to be timely and appropriate for the person and organization you are contacting. Following the most recent company news, alerts, and updates about the leads you are currently working on is the simplest and most convenient way to stay on top of them. Here are AbbVie latest news, alerts and updates.
AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why
First, AbbVie completed the blockbuster $63 billion acquisition of Allergen in 2020. That brought commercial-stage drugs, like Botox and Juvederm, to AbbVie. It also brought knowledge from Allergen's long research and development (R&D) programs in aesthetics, neuroscience, and eye care.
26 Dec 2023
AbbVie's on an Acquisition Binge. Could Your Favorite Biotech Stock Be Next?
The pharma giant's latest big buyout offer is for Cerevel Therapeutics ( CERE 11.37%), a clinical-stage company developing treatments for schizophrenia and other neurological conditions. Despite not having any approved products to sell yet, AbbVie offered Cerevel $8.7 billion in cash, or $45 per share.
8 Dec 2023
AbbVie to Acquire Cerevel for $8.7B, Growing Neuro Drug Pipeline
AbbVie has agreed to acquire Cerevel Therapeutics for $8.7 billion, in a deal designed to expand the buyer's pipeline with Cerevel's neuroscience and psychiatric drug candidates.
7 Dec 2023
AbbVie to acquire neuroscience drugmaker Cerevel Therapeutics for $8.7 billion
The deal is AbbVie's latest attempt to expand its drug pipeline as its top-selling treatments, such as Humira, face generic competition.
6 Dec 2023
AbbVie (ABBV) to Acquire ImmunoGen (IMGN) for $10.1 Billion
AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.
1 Dec 2023
AbbVie strikes deal to acquire Waltham's ImmunoGen for more than $10 billion
Pharmaceutical giant AbbVie said Thursday it has agreed to pay more than $10 billion to buy Waltham cancer drug maker ImmunoGen, in the largest acquisition of a Massachusetts company this year.
30 Nov 2023
FAQs for AbbVie
Explore frequently asked questions about AbbVie’s business, including founding details, header quarters, information on technology stack, industry listing, and other details.
What is AbbVie's official website?
The official website of AbbVie is abbvie.com You can find their contact number, email address, and headquarters by clicking here.
How many employees are working at AbbVie?
What industry is AbbVie in?
What is AbbVie's tech stack?
Where are AbbVie's headquarters?
Get instant access to B2B contact data across the web
Sign Up Today
